Talk Bio

Lilly signs up to $1.26B deal for Hanmi's GLP‑2 drug sonefpeglutide for short bowel syndrome and other indications

Biogen advances anti-tau Alzheimer’s drug diranersen despite mixed Phase 2 results

Hengrui and Kailera Advance Oral Ribupatide Obesity Pill on Positive Phase 2 Data Showing Up to 12% Weight Loss

Cynata Completes Patient Enrolment in Phase 2 aGvHD Clinical Trial

AC Immune Reports Promising Phase 2 Interim Data for Parkinson's Immunotherapy ACI-7104.056

Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

Novartis Acquires Tourmaline Bio for $1.4B to Bolster Cardiovascular Pipeline with Promising Phase 2 Drug

Servier Supercharges Neuro Pipeline with $450M Deal for Fragile X Syndrome Candidate

Scholar Rock's SMA drug helps Zepbound patients retain muscle in phase 2 trial

FDA Rejects Stealth BioTherapeutics' Rare Disease Drug but Leaves Door Open for Accelerated Approval

Tourmaline Bio's Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

Beacon's rare eye disease gene therapy signals vision function improvements in early phase 2 data

LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia

LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US

LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US